RxDoctor Payments Data

Arley Peter, MD

Cardiovascular Disease · Vero Beach, FLNPI 1952515116

Payments from drug & device makers

$52,572in general payments, 2019–2025

Across 501 payments — averaging $104.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$41K
  • Medtronic$3K
  • Abbott$1K
  • Boston Scientific$750
  • Novartis$555
  • Amgen$465
  • plus $6K from 37 others

What the payments were for

  • Speaking & faculty fees$36,50069%
  • Travel & lodging$4711%
  • Food & beverage$15,56730%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,572 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,366,376
Medicare patients
2,199
Services billed
20,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,196$1,316,156
EntrestoSacubitril/Valsartan390$429,320
XareltoRivaroxaban308$306,128
JardianceEmpagliflozin221$214,678
MultaqDronedarone Hcl86$100,827
FarxigaDapagliflozin Propanediol89$80,278
BrilintaTicagrelor61$47,614
Repatha SureclickEvolocumab32$26,760
Repatha SyringeEvolocumab33$23,162
VerquvoVericiguat20$22,550
Dabigatran EtexilateDabigatran Etexilate Mesylate60$21,091
Metoprolol Succinate1,063$15,808
VascepaIcosapent Ethyl15$14,523
Atorvastatin Calcium1,256$12,157
Ranolazine ErRanolazine82$10,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$449$1,316,1561,196 claims
NovartisEntresto$555$429,320390 claims
Johnson & JohnsonXarelto$260$306,128308 claims
Boehringer IngelheimJardiance$350$214,678221 claims
AstraZenecaFarxiga, Brilinta$463$127,892150 claims
Sanofi-aventis U.S. LLCMultaq$348$100,82786 claims
MerckVerquvo$409$22,55020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →